Yanping Luo

Yanping Luo is a highly accomplished professional in the field of cell biology and immunology, with extensive experience in developing innovative therapies for cancer treatment. Here are some key details about their career and background:

Professional Experience

Yanping Luo has held several significant positions in the biopharmaceutical industry:

Current Roles::

• Director of Cell Biology at Gilead Sciences (February 2023 - Present)1
• Director of Cell Biology at Kite Pharma (February 2023 - Present)1

Previous Positions::

• Director of Translational Research at Tmunity Therapeutics Incorporated (April 2021 - February 2023)1
• Principal Scientist/In vivo pharmacology lead at Legend Biotech (March 2019 - April 2021)1
• Research Project Lead at BlueSphere Bio (January 2018 - March 2019)1
• Research Scientist at the Center for Cellular Immunotherapies, University of Pennsylvania (July 2014 - December 2017)1

Achievements at Legend Biotech

During their time as Principal Scientist at Legend Biotech, Yanping Luo:

• Developed an innovative TCR screening platform that successfully delivered new binders responding to critical targets of interest1
• Led a growing team of research scientists to develop new technologies and approaches for the TCR screening platform1
• Managed in vivo programs and CROs for evaluating the efficacy and safety of the company's TCR-T pipelines1
• Participated in business development analysis and evaluation, initiating a 2-year $1.6M collaboration with the University of Pennsylvania1

Educational Background

Yanping Luo has a strong academic foundation in immunology:

• Ph.D. in Immunology from the University of Chinese Academy of Sciences (2003-2011)1
• Ph.D. exchange student in Immunology at the University of Pennsylvania (2006-2011)1
• Bachelor of Science in Biology/Aquaculture from Guangdong Ocean University (1999-2003)1

Their research experience includes work on IgD in teleost fish and the cross-talk between complement and toll-like systems in fish immunology.1

Yanping Luo's career trajectory demonstrates a consistent focus on advancing cell therapies and immunotherapies for cancer treatment, with a particular emphasis on CAR-T and TCR-T technologies.